Clinical trials sponsored by Shengjing Hospital

Phase breakdown

Conditions studied

Recruiting trials led by Shengjing Hospital

• 3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
  NCT06205992 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• 3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension
  NCT05475015 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
  NCT04136782 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: Female · 7 locations
• Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy
  NCT05241119 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: Female · 2 locations
• Birth Cohort Study of China Medical University
  NCT03561766 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 1 location
• Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer
  NCT04065321 · Phase: Not specified · Ages: 18 Years to 60 Years · Sex: Female · 2 locations
• DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast
  NCT04052893 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years to 75 Years · Sex: Female · 3 locations
• Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
  NCT04983121 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B
  NCT06779058 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Multifrequency MRE in Evaluation of Chronic Kidney Diseases
  NCT06202235 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
  NCT05228951 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
  NCT06340230 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
  NCT04476485 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: Female · 12 locations
• Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC
  NCT06165900 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer
  NCT06698679 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 1 location
• The Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast Cancer
  NCT06690645 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 1 location
• The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
  NCT05263570 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 1 location
• The Shengjing Lung Cancer Cohort (SJ-LCC) Study on Risk Factors for Disease Development and Progression
  NCT07779005 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT
  NCT04137653 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location

Common questions

How many trials is Shengjing Hospital recruiting for?

Shengjing Hospital is the lead sponsor of 19 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.